Overview
(A Development Stage Company)
Redpoint Bio believes a spoonful of sugar helps the medicine go down. So, the development stage biotechnology company is developing compounds that make foul medicines, foods, and drinks a thing of the bitter past. The company is working on developing bitter blockers, compounds that will prevent taste buds from sensing bitter flavors in pharmaceutical products. It is also developing flavor enhancers which will amplify sweet, savory, and salty taste
...
Read More sensations in foods and beverages, and possibly make processed foods and drinks healthier. Redpoint Bio was founded in 1995 by Robert Margolskee to capitalize on a taste-specific protein he discovered four years earlier.
Read Less
Read More sensations in foods and beverages, and possibly make processed foods and drinks healthier. Redpoint Bio was founded in 1995 by Robert Margolskee to capitalize on a taste-specific protein he discovered four years earlier.
Read Less
SCOTT HORITZ
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biological research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
#
Actual
? %
?
?
Contacts
Get in Touch with 3 Principals* and 1 Contacts
-
SCOTT HORITZPresident
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of ? (12 month period) in USD
Annual Revenue
?
USD
Modelled
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2011 | 2010 | 2009 |
|---|---|---|---|
| Net Operating Cash | -$1 | -$4 | -$8 |
| Net Investing Cash | $0 | $ | $11 |
| Net Financing Cash | -$0 | -$0 | -$0 |
| Net Change in Cash | -$1 | -$4 | $2 |
| Cash at Beginning of Period | $1 | $6 | $3 |
| Cash at End of Period | $0 | $1 | $6 |
| Capital Expenditure | $ | $ | -$0 |
| Assets (mil) | 2011 | 2010 | 2009 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $0 | $1 | $6 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $0 | $0 | $0 |
| Asset Summary | |||
| Total Current Assets | $0 | $1 | $6 |
| Tangible Fixed Assets | $ | $0 | $1 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $0 | $2 | $7 |
| Liabilities (mil) | 2011 | 2010 | 2009 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0 | $1 | $1 |
| Short-Term Debt | $ | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 |
| Liability Summary | |||
| Total Current Liabilities | $0 | $2 | $1 |
| Long-Term Debt | $ | $0 | $1 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $0 | $2 | $2 |
| Stakeholder's Equity (mil) | 2011 | 2010 | 2009 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$57 | -$57 | -$51 |
| Equity Summary | |||
| Total Equity | -$0 | -$0 | $5 |
| Shares Outstanding | 79,914,879 | 79,846,893 | 79,838,693 |